Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Director | March 24, 2026 | March 25, 2026 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director · Chief Executive Officer | July 08, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pyxis Oncology, Inc.
Report date March 24, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-03-24 | Direct | 45,867 |
Reported balance
After 2026-03-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-24 · Grant · Acquired 45,867 · Balance 45,867 F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.
Syndax Pharmaceuticals Inc
Report date July 08, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 484,843 |
Ending reported balance
After 2026-07-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-08 · Exercise / conversion · Acquired 32,375 · Balance 517,218 Row 2 · 2026-07-08 · Sale · Disposed 32,375 · Balance 484,843 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,564,551 options to purchase shares of common stock that are vested and immediately exercisable and a total of 813,949 options to purchase shares of common stock that have not yet vested. F2: The sale prices ranged from $24.00 to $24.43 |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2029-02-06 | Direct | 0 |
Reported balance
After 2026-07-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-08 · Exercise / conversion · Acquired 32,375 · Balance 0 F3: This option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,564,551 options to purchase shares of common stock that are vested and immediately exercisable and a total of 813,949 options to purchase shares of common stock that have not yet vested.
F2: The sale prices ranged from $24.00 to $24.43
F3: This option is fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CTI BIOPHARMA CORP
Report date June 26, 2023 · Filed June 26, 2023
Section 16 reporting ended · disclosed 2023-06-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-26 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.61 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-26 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-26 · Disposition to issuer · Disposed 63,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)
F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 1,280 | $25.02 | $32,026.37 |
DisclosureSEC source: 0001562180-22-007012 · primarydocument.xml · nonDerivative · entry 6 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 690,759 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $25.00 to $25.03. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 1,280 | $8.77 | $11,225.60 |
DisclosureSEC source: 0001562180-22-007012 · primarydocument.xml · nonDerivative · entry 5 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 2,883 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001562180-22-007012 · primarydocument.xml · derivative · entry 8 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,883 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 2,883 | $25.01 | $72,106.71 |
DisclosureSEC source: 0001562180-22-007012 · primarydocument.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 690,759 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $25.00 to $25.03. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 2,883 | $8.77 | $25,283.91 |
DisclosureSEC source: 0001562180-22-007012 · primarydocument.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 29,606 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001562180-22-007012 · primarydocument.xml · derivative · entry 7 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,606 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 29,606 | $25.02 | $740,756.92 |
DisclosureSEC source: 0001562180-22-007012 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 690,759 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $25.00 to $25.15. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 29,606 | $8.77 | $259,644.62 |
DisclosureSEC source: 0001562180-22-007012 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 11,838 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-22-005761 · primarydocument.xml · derivative · entry 6 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,838 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vests periodically upon the Issuer achieving certain milestones. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 19,764 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-22-005761 · primarydocument.xml · derivative · entry 5 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,764 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests in 48 successive equal monthly installments measured from 02/06/2019. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 11,838 | $21.06 | $249,253.83 |
DisclosureSEC source: 0001562180-22-005761 · primarydocument.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 670,466 options to purchase shares of common stock that are vested and immediately exercisable and a total of 539,063 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $21.00 to $21.16. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 11,838 | $6.38 | $75,526.44 |
DisclosureSEC source: 0001562180-22-005761 · primarydocument.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 19,764 | $21.06 | $416,138.93 |
DisclosureSEC source: 0001562180-22-005761 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 670,466 options to purchase shares of common stock that are vested and immediately exercisable and a total of 539,063 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $21.00 to $21.16. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 19,764 | $6.38 | $126,094.32 |
DisclosureSEC source: 0001562180-22-005761 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:51 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 100 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · derivative · entry 6 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests periodically upon the Issuer achieving certain milestones. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:51 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 100 | $21.00 | $2,100.00 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 702,068 options to purchase shares of common stock that are vested and immediately exercisable and a total of 554,172 options to purchase shares of common stock that have not yet vested. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:51 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 100 | $6.38 | $638.00 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 16:51 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 1,100 | $6.55 | $7,205.00 |
DisclosureSEC source: 0000891293-22-000036 · primary_doc.xml · nonDerivative · entry 6 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 16:51 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 400 | $6.54 | $2,616.00 |
DisclosureSEC source: 0000891293-22-000036 · primary_doc.xml · nonDerivative · entry 5 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 16:51 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 400 | $6.53 | $2,612.00 |
DisclosureSEC source: 0000891293-22-000036 · primary_doc.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 16:51 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 3,321 | $6.52 | $21,652.92 |
DisclosureSEC source: 0000891293-22-000036 · primary_doc.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 16:51 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 5,900 | $6.51 | $38,409.00 |
DisclosureSEC source: 0000891293-22-000036 · primary_doc.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,221 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 16:51 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 9,000 | $6.50 | $58,500.00 |
DisclosureSEC source: 0000891293-22-000036 · primary_doc.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,121 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:51 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 15,009 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · derivative · entry 5 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,009 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests periodically upon the Issuer achieving certain milestones. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:51 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 15,009 | $21.07 | $316,307.17 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 702,068 options to purchase shares of common stock that are vested and immediately exercisable and a total of 554,172 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $21.00 to $21.25. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:51 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 15,009 | $6.38 | $95,757.42 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:02 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 91,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-22-000035 · primary_doc.xml · derivative · entry 6 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 91,500 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying the option were fully vested on May 16, 2020, the date that is twelve months after the date of grant. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:02 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 3,331 | $6.23 | $20,737.14 |
DisclosureSEC source: 0000891293-22-000035 · primary_doc.xml · nonDerivative · entry 5 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,121 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.21 to $ 6.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:02 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 27,506 | $6.14 | $168,895.09 |
DisclosureSEC source: 0000891293-22-000035 · primary_doc.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,452 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.11 to $ 6.20. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:02 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 51,963 | $6.05 | $314,438.51 |
DisclosureSEC source: 0000891293-22-000035 · primary_doc.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,958 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.00 to $ 6.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:02 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 8,700 | $5.98 | $51,996.42 |
DisclosureSEC source: 0000891293-22-000035 · primary_doc.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,921 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.95 to $ 5.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:02 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 91,500 | $0.84 | $76,960.65 |
DisclosureSEC source: 0000891293-22-000035 · primary_doc.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 19:43 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0000899243-22-010776 · doc4.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: This stock option vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2023 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:33 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 325,000 | $15.79 Strike: $15.79 | $5,131,750.00 |
DisclosureSEC source: 0001562180-22-001081 · primarydocument.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The securities awarded on 02/02/2022 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 245,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/02/2022. Options to purchase 80,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 16,000 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · derivative · entry 12 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 45,000 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · derivative · entry 11 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 45,000 | $20.29 | $912,960.00 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · nonDerivative · entry 8 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 596,031 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested. F4 · price: The sale prices ranged from $19.17 to $21.01 Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 45,000 | $8.77 | $394,650.00 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · nonDerivative · entry 7 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 16,000 | $20.29 | $324,608.00 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · nonDerivative · entry 6 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 596,031 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested. F4 · price: The sale prices ranged from $19.17 to $21.01 Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 16,000 | $6.38 | $102,080.00 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · nonDerivative · entry 5 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 1,676 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · derivative · entry 10 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,676 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 1,676 | $19.02 | $31,877.18 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 596,031 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $19.00 to $19.06. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 1,676 | $6.38 | $10,692.88 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 22,715 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · derivative · entry 9 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,715 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 22,715 | $19.08 | $433,399.93 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 596,031 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $19.00 to $19.30. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 22,715 | $6.38 | $144,921.70 |
DisclosureSEC source: 0001562180-21-007809 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 22:35 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 34,564 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-21-007710 · primarydocument.xml · derivative · entry 6 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,564 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 22:35 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 2,045 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-007710 · primarydocument.xml · derivative · entry 5 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,045 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 22:35 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 34,564 | $19.05 | $658,554.80 |
DisclosureSEC source: 0001562180-21-007710 · primarydocument.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 681,422 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $19.00 to $19.49. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 22:35 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 34,564 | $6.38 | $220,518.32 |
DisclosureSEC source: 0001562180-21-007710 · primarydocument.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.